Aerodynamic characteristics of nebulized terbutaline sulphate using the Andersen Cascade Impactor compared to the Next Generation Impactor

Pharmaceutical Development and Technology

Volumn 16, Issue 2, 2011, Pages 137-145

  Abdelrahim, Mohamed E ^a  

^a Beni Suef University   (Egypt)

Author keywords

Andersen Cascade Impactor; cooling; flow rate; evaporation; nebulizer; Next Generation Impactor; Terbutaline sulphate

Indexed keywords

TERBUTALINE SULFATE;

AEROSOL; ANDERSEN CASCADE IMPACTOR; ARTICLE; COLD; COOLING; EVAPORATION; FLOW RATE; INTERMETHOD COMPARISON; NEBULIZATION; NEBULIZER; NEXT GENERATION IMPACTOR; PARTICLE SIZE; PRIORITY JOURNAL; ROOM TEMPERATURE;

BRONCHODILATOR AGENTS; EQUIPMENT DESIGN; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; TERBUTALINE;

EID: 79953031097     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450903511194     Document Type: Article

References (29)

1. Boe J, Dennis J, O'Driscoll B, Members of Task Force, Bauer T, Carone M, et al. European Respiratory Society Guidelines on the use of nebulizers: Guidelines prepared by a European Respiratory Society Task Force on the use of nebulizers. Eur Respir J 2001;18(1):228-242.
2. Comité-Européen-Normalisation. Respiratory therapy equip-ment. Part 1: Nebulizing system and their componants. prEN 13544-1. CEN Brssels, Belgium. 2001:33-38.
3. Jauernig J, Hug M, Knoch M. Contribution to the aerodynamic par-ticle size assessment of nebulized drugs using the next generation impactor (NGI). Drug Delivery to the Lungs XIII Aerosol Society, London, UK. 2002:44-47.
4. Jauernig J, Ohl S, Knoch M, Keller M. Efects of the test set-up formulation, and nebulizer type on aerodynamic droplet characteristics. Resp Drug Deliv 2004;IX:609-612.
5. Mazhar S, Ismail N, Newton D, Chrystyn H. Relative lung depo-sition of salbutamol following inhalation from a spacer and a Sidestream jet nebuliser following an acute exacerbation. Brit J Clin Pharmacol 2008;65(3):334-337. (Pubitemid 351316916)
6. Abdelrahim ME, Chrystyn H. Aerodynamic characteristics of nebulized terbutaline sulphate using the Next Generation Impactor (NGI) and CEN method. J Aerosol Med Pulm Drug Deliv 2009;22(1):19-28.
7. British Pharmacopoeia. Preparations for inhalation. Aerodynamic assessment of fne particles-fne particle dose and particle size distribution (Ph. Eur. method 2.9.18). In: Stationery Ofce, editor. British Pharmacopoeia. London; 2005. p. A277-290.
8. United States Pharmacopeia. Aerosols, nasal sprays, metered dose inhalers and dry powder inhalers. Te United States pharmacopeia 28 [and] Te national formulary 23: Te board of trustees; 2005. pp 2359-2377.
9. Nadarassan DK, Clark BJ, Assi K, Chrystyn H. Use of a mixing valve allows In-vitro characterisation of the emitted dose from a dry powder inhaler (DPI) using a low inhalation fow. J Aerosol Med 2007 2007;20(2):188.
10. Finlay WH, Stapleton KW, Zuberbuhler P. Predicting regional lung dosages of a nebulized suspension: Pulmicort® (budesonide). Particul Sci Technol 1997;15(3):243-251. (Pubitemid 28449121)
11. Jauernig J, Schuschnig U, Hug M, Keller M. Validation of a test set-up utilizing the 28.3 L/min Andersen Cascade Impactor (ACI) for the aerodynamic assessment of nebulized aqueous formulations. Respiratory Drug Delivery VIII. 2002;2:537-539.
12. Jauernig J, Schuschnig U, Hinrichs C, Hug M, Keller M. Comparative assessment of the aerodynamic droplet deposition pattern in an Andersen and Marple 298 impactor. J Aerosol Med 2001;14(3):405.
13. Finlay WH, Stapleton KW. Undersizing of droplets from a vented nebulizer caused by aerosol heating during transit through an anderson impactor. J Aerosol Sci 1999;30(1):105-109. (Pubitemid 28488411)
14. Marple V, Roberts D, Jolyon M. A proposal for the use of the Next generation impactor (NGI) at fow rates between 15 and 30 L/min. Resp Drug Deliv 2004;IX:701-704.
15. Marple V, Olson B, Santhanakrishnan K, Roberts D, Mitchell J, Hudson-Curtis B. Next Generation pharmaceutical Impactor: A new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aerosol Med 2004;17(4):335-343. (Pubitemid 40116950)
16. Berg E, Svensson JO, Asking L. Determination of nebulizer drop-let size distribution: A method based on impactor refrigeration. J Aerosol Med. 2007;20(2):97-104. (Pubitemid 46870213)
17. Jauernig J, Ohl S, Luber M, Keller M. Diferences in results obtained with the next generation impactor (NGI) for Pulmicort® suspension and according to the CEN standard EN13544-1 for a NaFSolution. Resp Drug Deliv 2003;XIV:41-44.
18. Berg E, Asking L. Nebulizer droplet size distribution-refrigerated NGI at 15 L/min. Resp Drug Deliv 2004; IX: 361-363.
19. Dennis J, Berg E, Sandell D, Ali A, Lamb P, Tservistas M, et al. Cooling the NGI-an approach to size a nebulised aerosol more accurately. PharmEuropa Sci Notes 2008;1:27-30.
20. Berg E, Lamb P, Ali A, Dennis J, Tservistas M, Mitchell J. Assessment of the need to coat particle collection cups of the NGI to mitigate droplet bounce when evaluating nebuliser-produced droplets. PharmEuropa Sci Notes 2008;1:21-26.
21. Tservistas M, Reul K, Luithlen A, Friedrich I, Bucholski A, Keller M. Correlation of data from Andersen and Next Generation Impactor compared to laser difractometry. J Aerosol Med 2006;19(2):231.
22. Zhou Y, Brasel TL, Kracko D, Cheng Y-S, Ahuja A, Norenberg JP, et al. Infuence of impactor operating fow rate on particle size distribution of four jet nebulizers. Pharmaceut Develop Technol 2007;12(4):353-359. (Pubitemid 47347138)
23. Van Oort M. In vitro testing of dry powder inhalers. Aerosol Sci Technol 1995;22(4):364-373.
24. Hinds WC. Aerosol technology: Properties, behavior, and measurement of airborne particles: New York: Wiley-Interscience; 1999.
25. Waldrep JC, Berlinski A, Dhand R. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J Aerosol Med 2007;20(3):310-319. (Pubitemid 47463184)
26. Garmise RJ, Hickey AJ. Calibration of the Andersen cascade impactor for the characterization of nasal products. J Pharm Sci 2008;97(8):3462-3466.
27. Bennett WD, Zeman KL. Sizing evaporative aerosols: Te man with too many watches dilemma. J Aerosol Med Pulm Drug Deliv 2009;22(1):3-4.
28. Dennis J. Evolution of evaporative understanding within nebulizer standards. J Aerosol Med Pulm Drug Deliv 2009;22(1):5-8.
29. Zhou Y, Ahuja A, Irvin CM, Kracko DA, McDonald JD, Chen YS. Medical nebulizer performance: Efects of Cascade Impactor temperature. Respir Care 2005;50(8):1077